Exclusive: XCures Lands $46M Series B To Clean Up Messy Medical Records With AI
xCuresCompany
Innovius CapitalInvestor
iGrowInvestor
Spring Mountain CapitalInvestor
xCures closed a $46 million Series B on June 24, 2026, led by Innovius Capital with participation from iGrow and Spring Mountain Capital, valuing the AI‑driven health‑tech SaaS at $127 million post‑money.
xCures announced the close of a $46 million Series B financing on June 24, 2026, led by Innovius Capital and joined by iGrow and Spring Mountain Capital. The round lifts the company’s total capital raised to more than $76 million and places its post‑money valuation at $127 million, more than double the $25 million Series A valuation from December 2023.
Deal Terms
The Series B injects growth capital as xCures scales its usage‑based SaaS platform, which reported roughly $3 million in annualized recurring revenue (ARR) in 2024 and grew to $10 million in 2025. Management projects ARR to breach $20 million in 2026, implying a valuation multiple of roughly 6.3 times forward ARR. The round also saw participation from existing backers, underscoring continued confidence in the company’s AI‑driven data‑cleaning engine.
Business Pivot and Product
Founded in 2018 as a cancer‑patient decision‑support tool, xCures pivoted after encountering “dirty data” bottlenecks in patient records. The firm now offers a Clinical Clarity Engine that ingests unstructured medical documents from over 550,000 locations, normalizes them, and delivers decision‑ready checklists. To date the engine has processed more than 300 million records, serving enterprise customers such as Exact Sciences, Caris Life Sciences, and Novocure, as well as large hospital networks and Medicare Advantage plans.
Growth Outlook
Having achieved cash‑flow breakeven in 2025, xCures entered a capital‑burn phase to expand its team and product roadmap ahead of a 2027 pipeline. The company’s enterprise client base of 25 organizations is expected to grow as hospitals adopt the engine for operating‑room scheduling, comorbidity screening, and prior‑authorization automation. The fresh capital will fund deeper integration with national health‑information exchanges and accelerate the rollout of proprietary governance frameworks that keep AI outputs clinically sound.
Why It Matters
The infusion of $46 million positions xCures to outpace rivals that merely transport health data, allowing it to deepen its clinical‑intelligence layer and lock in enterprise contracts. Competitors such as Health Catalyst and Flatiron will need to accelerate their own data‑normalization capabilities or risk losing market share in the emerging “clinical clarity” niche.
For investors, the round validates a broader appetite for AI‑enabled health‑tech platforms that can monetize large‑scale data cleaning under a SaaS model. Innovius Capital’s backing signals confidence that xCures can become a foundational data layer for the industry, potentially prompting further consolidation as larger health‑IT firms seek to acquire or partner with specialized AI data providers.
Key Points
- xCures raised $46 million in a Series B led by Innovius Capital on June 24, 2026.
- The round values the company at $127 million post‑money, more than double its Series A valuation.
- ARR grew from $3 million in 2024 to $10 million in 2025, with a target of $20 million in 2026.
- The Clinical Clarity Engine has processed over 300 million medical records from 550,000+ locations.
- Enterprise client roster now includes Exact Sciences, Caris Life Sciences, and Novocure.
Analysis
At a $127 million post‑money valuation and projected $20 million ARR for 2026, xCures trades at roughly a 6‑multiple, comfortably within the 5‑10× range typical for AI‑enabled health‑tech SaaS firms. The round underscores a sector‑wide shift toward monetizing the “dirty data” problem that has long hampered clinical workflows. Operators that can embed AI‑driven normalization into existing EHR ecosystems stand to capture higher net revenue retention as hospitals automate prior‑authorizations and risk‑stratification. For investors, the deal highlights the premium placed on platforms that combine proprietary models with commercial frontier AI, suggesting that future rounds may tilt toward valuation‑driven growth rather than pure cash‑burn. As the market approaches $15‑$16 billion in AI health‑tech funding this year, we can expect intensified M&A activity, with larger health‑IT vendors eyeing acquisitions of niche data‑layer specialists like xCures to accelerate their own AI roadmaps.